Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
memantine · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| memantine | DRUG | - |
Inclusion Criteria: * glaucoma damage on examination of visual field and optic disc * good visual acuity (with glasses if needed)
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | Bimatoprost |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Nicotinomide |
| Alcon AG | ALC | 3 | PHASE4 | Undisclosed |
Memantine is an investigational small molecule being studied for the treatment of open-angle glaucoma, a chronic condition characterized by increased intraocular pressure and progressive optic nerve damage. It is being evaluated as a potential neuroprotective therapy to slow disease progression. Memantine is not approved for this indication and remains in clinical development.
Memantine is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. AbbVie is conducting clinical trials to evaluate the safety and efficacy of memantine in patients with open-angle glaucoma.
Memantine is in Phase 3 clinical development for open-angle glaucoma. Two Phase 3 trials have been completed, with a total of 2,298 patients enrolled. The drug is investigational and has not received regulatory approval for this use.
Memantine has been studied in two completed Phase 3 clinical trials for open-angle glaucoma: NCT00141882, which enrolled 1,119 patients, and NCT00168350, which enrolled 1,179 patients. Both trials were randomized, double-blind, and included adult patients aged 18 years and older.
Memantine is the generic name for a drug that is also known by the brand name Namenda, which is approved for Alzheimer's disease. However, in the context of open-angle glaucoma, memantine is being investigated as a novel therapy and is not approved for this condition.